>>Even given the small subgroup and the Halabi nomogram estimated accuracy of 69%, a suggested benefit in median survival of over 20 months is impressive.<<
Check your math, rancherho!
>>IMO, the sometimes expressed theory that only the healthier patients would select docetaxel afer Provenge or GVAX is dubious, especially where Drs. Petrylak and Small both use Halabi as a standard reference.<<
Halabi's nomogram was essentially pre-taxotere.
>>At the end of the study 13 of 34 patients in the radiologic group received subsequent chemotherapy (taxane in 9/13); their median survival was more than 35.2 months (95%CI, 29, 44). The median survival of the non-chemotherapy treated patients was 17.2 months (95% CI, 9, 32).<<
Point made, but note the size of them thar error bars!
>>17.2 months (95% CI, 9, 32).<<
Fold the statistical errors in with the self selection ("dead men don't take chemo") and it would seem the jury is at least not unanimous.
micro
Life is an IQ test.
email: microcapfun@yahoo.com